LOUISVILLE, Colo., April 6 /PRNewswire/ -- Replidyne, Inc. today announced that it has filed a registration statement with the Securities and Exchange Commission for a proposed initial public offering of its common stock. All of the shares will be issued and sold by Replidyne.
Merrill Lynch & Co. and Morgan Stanley are acting as joint book-running managers for the offering and Cowen & Co., LLC and Pacific Growth Equities, LLC are acting as co-managers.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
When available, copies of the preliminary prospectus relating to the offering may be obtained from: Merrill Lynch & Co., 4 World Financial Center, New York, New York 10080 (telephone: 212-449-1000) or Morgan Stanley, Prospectus Department, 1585 Broadway, New York, New York 10036 (telephone: 212-761-4000).
Replidyne, Inc.
CONTACT: Mark Smith, Chief Financial Officer of Replidyne, Inc.,+1-303-996-5503
